Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
Summary not available.
DBV Technologies announced a conference call for May 2, 2022, at 5:00 p.m. ET to discuss its first quarter 2022 financial results and corporate updates. The call will be available via teleconference and live webcast. DBV is focused on developing Viaskin™, a platform for epicutaneous immunotherapy aimed at treating food allergies, with ongoing trials for Viaskin Peanut. The company's shares are traded on Euronext and Nasdaq under the symbols DBV and DBVT, respectively.
DBV Technologies will hold its Ordinary and Extraordinary General Meeting on May 12, 2022, at 8:30 a.m. CEST in Montrouge, France. Preparatory documents are available on the company's website and via the French Bulletin des Annonces Légales Obligatoires. Shareholders can request documents until May 7, 2022, and the meeting will also be webcast live. DBV is focused on developing Viaskin™, an innovative platform for immunotherapy targeted at food allergies, with ongoing clinical trials for Viaskin Peanut.
The monthly report as of March 31, 2022, reveals that DBVT has a total of 55,095,537 shares outstanding. The total number of voting rights attached to these shares is 55,095,537, with a net total of 54,951,036 voting rights. This net total accounts for shares without voting rights. The report is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is intended for shareholders and market observers.
DBV Technologies will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 10:00 a.m. ET. Dr. Pharis Mohideen, the Chief Medical Officer, is set to deliver the presentation. Investors can access the webcast on the company's website, with a replay available for about 90 days post-event. DBV Technologies focuses on developing Viaskin™, an innovative technology platform for immunotherapy, particularly aimed at food allergies, with ongoing trials for Viaskin Peanut.
DBVT announced its monthly update as of February 28, 2022, regarding the total number of shares and voting rights. The company reported a total of 55,095,762 shares, with a total gross of 55,095,762 voting rights. After accounting for shares without voting rights, the total net voting rights stood at 54,919,952. This information is in compliance with the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced the filing of its 2021 Annual Report on Form 10-K with the SEC and its 2021 Universal Registration Document with the French AMF. Both documents are accessible on the company's investor website and the respective regulatory authority sites. DBV Technologies is focused on developing the Viaskin™ platform for food allergies using epicutaneous immunotherapy, with ongoing trials for Viaskin Peanut. The company operates globally from Montrouge, France, and Summit, NJ, and its shares are listed on Euronext and Nasdaq under the ticker DBVT.
DBV Technologies reported its 2021 financial results, revealing a net loss of $97.8 million, down from $159.6 million in 2020. The company's cash and cash equivalents decreased to $77.3 million from $196.4 million in 2020. Operating income fell to $5.7 million, primarily due to reduced revenue from a collaboration with Nestlé. However, DBV extended its cash runway into Q1 2023 through cost containment measures. The pivotal protocol for the modified Viaskin Peanut patch is complete and ready for FDA submission, highlighting ongoing discussions with the FDA aimed at advancing its research and development efforts.
DBV Technologies will report its full year 2021 financial results on March 3, 2022. The company, based in Montrouge, France, is focused on developing the Viaskin platform for immunotherapy, specifically for food allergies. A conference call will be held at 5:00 p.m. ET to discuss the financial outcomes and provide corporate updates. The call can be accessed via specified teleconferencing numbers and a live audio webcast will be available on their website.
DBV Technologies (DBVT) will participate in the AAAAI 2022 Congress from February 24-28, 2022. They will present two scientific posters: one on allergy specialty care effects on healthcare utilization in children with peanut allergies and another on pooled safety data from Phase 3 trials of their Viaskin Peanut treatment. Viaskin Peanut aims to reduce allergic reactions in children aged 4-11. The presentations will be available on-demand for registered attendees and later on DBV's website.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
